
    
      This is a single arm, phase II, multicenter study trial evaluating Pembrolizumab in recurrent
      platinum resistant CPS score >1 positive ovarian, Fallopian tube and primary peritoneal
      cancer patients. All the eligible patients will receive Pembrolizumab 200 mg d1 q 21 iv
      infusion in 30 minutes, until disease progression of disease, unacceptable toxicity or
      patient's refusal. Pembrolizumab will be administered for a maximum of 2 years.

      The primary objective of the study is to assess overall survival (OS) of patients treated
      with Pembrolizumab single agent.
    
  